GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » Price-to-Owner-Earnings

Vera Therapeutics (Vera Therapeutics) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-07), Vera Therapeutics's share price is $38.035. Vera Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Vera Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


VERA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), Vera Therapeutics's share price is $38.035. Vera Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.05. Therefore, Vera Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-07), Vera Therapeutics's share price is $38.035. Vera Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.05. Therefore, Vera Therapeutics's PE Ratio without NRI for today is At Loss.


Vera Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Vera Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vera Therapeutics Price-to-Owner-Earnings Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Vera Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vera Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Vera Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vera Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vera Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Vera Therapeutics's Price-to-Owner-Earnings falls into.



Vera Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Vera Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=38.035/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vera Therapeutics  (NAS:VERA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Vera Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Vera Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Vera Therapeutics (Vera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Executives
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Marshall Fordyce director, officer: President and CEO C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Celia Lin officer: Chief Medical Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley officer: Chief Development Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Sean Grant officer: Chief Financial Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg director
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Abingworth Bioventures 8 Lp 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Vera Therapeutics (Vera Therapeutics) Headlines